stoxline Quote Chart Rank Option Currency Glossary
  
Ampio Pharmaceuticals, Inc. (AMPE)
0.0027  0 (0%)    06-11 20:00
Open: 0.07825
High: 0.07825
Volume: 1
  
Pre. Close: 0.0027
Low: 0.0027
Market Cap: 0(M)
Technical analysis
2025-06-12 4:45:47 PM
Short term     
Mid term     
Targets 6-month :  0.09 1-year :  0.15
Resists First :  0.08 Second :  0.13
Pivot price 0.03
Supports First :  0 Second :  0
MAs MA(5) :  0.08 MA(20) :  0.02
MA(100) :  0 MA(250) :  0.01
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  53 D(3) :  66.1
RSI RSI(14): 45.8
52-week High :  0.44 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMPE ] has closed above bottom band by 35.4%. Bollinger Bands are 704.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.08 - 0.08 0.08 - 0.08
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Headline News

Sat, 10 May 2025
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World

Mon, 25 Mar 2024
Ampio Announces Voluntary Delisting and SEC Deregistration - PR Newswire

Thu, 11 Jan 2024
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions - PR Newswire

Thu, 31 Aug 2023
Ampio Pharmaceuticals Announces Reverse Stock Split - PR Newswire

Sun, 09 Oct 2022
AMPE Stock Price and Chart — OTC:AMPE - TradingView

Wed, 03 Aug 2022
Ampio Pharmaceuticals Issues Letter to Stockholders - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
OTC
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 1.5 (%)
Held by Institutions 0 (%)
Shares Short 33 (K)
Shares Short P.Month 35 (K)
Stock Financials
EPS -10.66
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.03
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -61.6 %
Return on Equity (ttm) -114 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -8.24
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android